Conferences, Events and Publications

ACI Homepage

ACI Blog Homepage

ACI Expert Jobs

Posts Tagged ‘FDA’

« Older Entries

Weekly Industry News – Pharma & Healthcare

March 17th, 2014
in Healthcare, Legal Conferences, Pharmaceuticals / Biotech / Life Sciences |

Pharma & Healthcare – the latest on FDA’s proposed generic drug labeling rule, FDA bans imports from India’s Sun Pharma and more.

(more…)

Weekly Industry News: Pharma & Healthcare

February 10th, 2014
in Healthcare, Legal Conferences, Litigation, Pharmaceuticals / Biotech / Life Sciences |

Pharma & Healthcare – the latest on Pfizer Inc v. Teva Pharmaceuticals, the USFDA imposes penalties on Indian pharma cos’ and more.

 

FDA panel could give Bayer painkiller an edge over rivals from Pfizer, J&J by Tracy Staton Published on  FiercePharma.com

What if every drug in a class posed a risk to the heart–all except one? That’s the question we could soon be asking about nonsteroidal anti-inflammatories, or NSAIDs, among the most commonly used drugs in the world… [ Read More ]

‘USFDA has imposed disproportionate penalties on Indian pharma cos’ by Amiti Sen Published on The Hindu Business Line

Reacting strongly to the recent string of actions against Indian pharmaceutical companies by the US Food & Drug Administration (FDA), India has said that in some cases the authority has imposed disproportionately strong penalties…[ Read More ]

Pfizer Inc. v. Teva Pharmaceuticals USA, Inc. (Fed. Cir. 2014) by Andrew Williams Published on jdsupra.com

The standard of review at the Federal Circuit is important.  Even though it often appears like cases are re-litigated at the Appeals Court, it is actually very difficult (or at least should be) to overturn a lower court’s factual determinations…[ Read More

Live Industry News

Twitter  Follow @ACI_Pharma & @ACI_Health

 

LinkedIn-Logo-2C (1)  Join ACI Pharmaceuticals/Biotech/Life Sciences Experts Group

Join ACI Healthcare: Legal, Regulatory, and Compliance Experts Group

Related Events

Pharma BioTech

Pharmaceutical Compliance & Enforcement 1

For the complete list of all Phamaceuticals  upcoming events: Click Here

For the complete list of all Healthcare upcoming events: Click Here

To download past Pharmaceuticals conference materials: Click Here

To download past Healthcare conference materials: Click Here 

FDA Steps up and forces recall of OxyElite Pro after a death and kidney failure in Hawaii

November 20th, 2013
in Food and Beverage, Legal Conferences, Litigation |

Expert Guest Entry  by Bill Marler, Originally Posted on MarlerBlog

From our good friends at the FDA:

Following actions by the Food and Drug Administration (FDA), a Texas-based company has agreed to recall and destroy a dietary supplement linked to dozens of cases of acute liver failure and hepatitis, including one death and illnesses so severe that several patients required liver transplants.

In addition to the recall of certain OxyElite Pro products, USPLabs assured FDA officials that it will destroy warehouse stocks of the supplement, with a retail value of about $22 million. FDA will oversee the destruction of the product.

“As soon as we suspected a possible link between OxyElite Pro products and cases of liver failure and non-viral hepatitis in Hawaii, we warned the public and immediately launched an investigation with state officials and the Centers for Disease Control and Prevention (CDC),” said Daniel Fabricant, Ph.D., director of FDA’s Division of Dietary Supplement Programs. “Our mandate to protect the public was fulfilled by ensuring the swift removal of the product from the marketplace.”

FDA used new enforcement tools provided by the FDA Food Safety Modernization Act to act quickly in the face of a potential danger to public health.

The supplement was advertised as an aid to losing weight and building muscles. FDA warned the company on Oct. 11, 2013, that certain OxyElite Pro products and another supplement, VERSA-1, are considered adulterated because they contain a new dietary ingredient, aegeline, for which the company did not provide evidence of safety.

While FDA’s investigation is still ongoing, the agency continues to warn consumers to avoid using OxyElite Pro and VERSA-1.

Earlier this year, a stockpile of another formulation of OxyElite Pro was destroyed after being held through an FDA administrative detention order. A stimulant included in those products, DMAA, or dimethylamylamine, can cause high blood pressure and lead to heart attacks, seizures, psychiatric disorders and death.

After removing DMAA from its products, USPLabs substituted aegeline, among other ingredients, in certain OxyElite Pro products. Non-synthetic aegeline is an alkaloid extract from leaves of the Asian bael tree (Agele marmelos).

“Twice in a short period, this company has added new dietary ingredients to supplements without notifying the FDA and providing a reasonable expectation of safety, as required by law,” said Fabricant. “Losses to the company should also serve as a reminder that FDA’s laws and regulations serve a purpose and must be followed.”

Related Events

Food Borne Illness           Food and Beverage

A Bunch of Listeria Recalls – Are there Illnesses?

October 29th, 2013
in Expert Guest Blog Entries, Food and Beverage, Legal Conferences |

Expert Guest Entry by William (Bill) Marler , Originally posted on MarlerBlog

On October 22, 2013, the FDA reported that Reser’s Fine Foods of Beaverton, OR was recalling approximately 109,000 cases of refrigerated ready-to-eat products because it may be contaminated withListeria monocytogenes.  The recalled refrigerated ready-to-eat products were distributed nationwide and Canada.

It reported:  NO illnesses have been reported to date.

On October 24, 2013, the FDA reported that Boston Salads and Prepared Foods of Boston, MA was voluntarily recalling prepared salads, because they have the potential to be contaminated with Listeria monocytogenes.  Product was distributed throughout the MA, CT, RI, VT, and ME states to wholesale and food service distributors, and retail stores.

It reported:  There has been no illness or complaints related to this recall.

On October 25, 2013, the FISS reported that Garden Fresh Foods of Milwaukee, WI was recalling approximately 103,080 additional pounds of ready-to-eat chicken and ham products due to possible contamination with Listeria monocytogenes.  The company was recalling these products in addition to the 25,748 pounds of similar products that were recalled on Sept. 25 and Oct. 17, 2013.

It reported:  FSIS and the company have not received reports of illnesses due to consumption of these products.

On October 25, 2013, the FSIS reported that Taylor Farms of Jessup, MD was recalling approximately 5,084 pounds of broccoli salad kit products.  The kits contain salad dressing in packets that were the subject of a Food and Drug Administration (FDA) recalldue to concerns about possible Listeria monocytogenes contamination.  The salad kits were shipped to distributors and retail locations (delis) for consumer purchase in Connecticut, Delaware, Maryland, Massachusetts, New Jersey, New York and Vermont.

It reported: FSIS, FDA and the company have received no reports of illnessesassociated with consumption of these products.

On October 26, 2013, the FSIS reported that Reser’s Fine Foods of Topeka, KS was expanding its recall of chicken, ham and beef products to include all products produced between Sept. 5 and Oct. 9, 2013. This was in addition to the 22,800 pounds of product recalled on Oct. 22, 2013. The products are being recalled due to possible contamination with Listeria monocytogenes.

It reported:  FSIS and the company have not received reports of illnesses due to consumption of these products.

Then on October 26, 2013 the FDA reported that Reser’s Fine Foods of Beaverton, OR was voluntarily expanding its October 22, 2013 recall of refrigerated ready-to-eat products because they may be contaminated with Listeria monocytogenes.  The recalled refrigerated ready-to-eat products were distributed nationwide and Canada.

Then it changed the wording regarding illnesses to:  There are no confirmed illnessesassociated with these products.

Illnesses linked to the above recalls or not?

 

Related Events

Food Borne Illness - Conference                                  Food and Beverage Conference

 

 

  For a complete list of all Food & Beverage upcoming events: Click Here
  For a list of past Food & Beverage conference proceedings: Click Here

Weekly Industry News – Pharma & Healthcare

October 28th, 2013
in Healthcare, Legal Conferences, Pharmaceuticals / Biotech / Life Sciences |

Pharma & Healthcare – The latest on Sun Pharma shares, Valeant Settlement, and more.

Sun Pharma shares fall after report about U.S. FDA queries by MUMBAI on Reuters 

Shares of Sun Pharmaceutical Industries Ltd(SUN.NS) fell as much as 2.1 percent after Bloomberg News reported the drug maker had received queries from the U.S. Food and Drug Administration over quality control at a U.S. subsidiary.

Sun received two so-called Form 483s, issued when the U.S. regulator has queries, for its Detroit-based Caraco Pharmaceutical Laboratories Ltd following inspections in January and May this year, Bloomberg reported on Monday, citing a Freedom of Information Act request… [ Read More ]

Valeant Pharma to pay Anacor $142.5M in settlement by Bloomberg Business Week on Bloomberg Business Week

NEW YORK (AP) — Valeant Pharmaceuticals will pay Anacor Pharmaceuticals $142.5 million in a settlement, the companies said Monday.

The payment will be made by Nov. 8, and it will resolve all disputes between Anacor and Valeant. That includes legal proceedings involving Medicis Pharma, which Valeant acquired in December.

Anacor says that Dow Pharmaceutical Services, which is now part of Valeant, breached a contract related to Anacor’s work on Jublia. The drug is a treatment for onychomycosis, a fungal infection of the nail and nail bed. On Oct. 18 an arbitrator awarded Anacor $100 million in damages and ordered Valeant to pay costs and attorney’s fees as well. Anacor, of Palo Alto, Calif., said it believed it had other claims against Valeant as well… [ Read More ]

Is It Pharma’s Fault That We Don’t Have Better Drugs For Malaria, TB And Tropical Diseases? by John LaMattina on Forbes

“Despite some high-profile commitments from some of the industry’s largest innovators, R&D for some of the world’s most deadly neglected diseases remains underfunded and unimpressive, according to a study, a state of affairs that has barely improved over the last three decades.”

 So starts an article by Damian Garde of FierceBiotech. Garde is referring to a recent paper in “The Lancet” entitled: “The drug and vaccine landscape for neglected diseases (2000 -11): a systematic assessment.”  Neglected diseases are defined as diseases that affect people in low-income countries and are the leading cause of mortality, chronic disability and poverty. They include malaria, tuberculosis, diarrheal diseases, and tropical diseases. The Lancet paper made the following points… [ Read More ]

Sun Pharma says issues with USFDA at Caraco facility addressed by The Economic Times

NEW DELHI: Drug maker Sun Pharmaceutical today said it has addressed the US health regulator’s concerns about manufacturing lapses at its US-based Caraco Pharmaceutical Laboratories.  United States Food and Drug Administration had conducted inspections in January and May this year and had noticed the lapses.

When asked about the nature of lapses and the corrective measures the company has taken a Sun Pharmaceutical spokesperson said they were “minor observations”.

“The company has responded to these a long time back,” the spokesperson said without elaborating.  Earlier in the August 2012, Sun Pharmaceutical Industries had said American health regulator had approved resumption of manufacturing operations at Caraco for two drugs after inspections of facilities… [ Read More ]

                                                              Related Events

Controlled Substances FDA Boot Camp - Devices Edition Rx Drug Pricing

Over the Counter Drugs  cGMP - Legal Conferences  Drug and Med Conference

 

For a complete list of all Pharma related upcoming events: Click Here

For a complete list of all Healthcare related upcoming events: Click Here

For a list of all past Pharma conference proceedings: Click Here

For a list of all past Healthcare conference proceedings: Click Here 

 

     Connect with us for live industry news:

 

     @ACI_Pharma   @ACI_Pharma             Pharma Linkedin Group ACI’s Pharmaceuticals Group
     @ACI_Healthcare@ACI_Health                  Healthcare LinkedIn GroupACI’s Healthcare Group

FDA finalizes new system to identify medical devices

October 23rd, 2013
in Legal Conferences, Pharmaceuticals / Biotech / Life Sciences |

Press Release from FDA, Released on 09/20/2013

 

Today, the U.S. Food and Drug Administration announced a final rule for the unique device identification system (UDI) that, once implemented, will provide a consistent way to identify medical devices.

The UDI system has the potential to improve the quality of information in medical device adverse events reports, which will help the FDA identify product problems more quickly, better target recalls, and improve patient safety. The FDA has worked closely with industry, the clinical community and patient and consumer groups in the development of this rule.

“UDI represents a landmark step in improving patient safety, modernizing our postmarket surveillance system for medical devices, and facilitating medical device innovation,” said Jeffrey Shuren, M.D., J.D., director of the FDA’s Center for Devices and Radiological Health.

The UDI system consists of two core items. The first is a unique number assigned by the device manufacturer to the version or model of a device, called a unique device identifier. This identifier will also include production-specific information such as the product’s lot or batch number, expiration date, and manufacturing date when that information appears on the label…. [ Read More ]

Related Event 

FDA Boot Camp - Devices Edition

 

When: Tuesday, November 05 to Wednesday, November 06, 2013

Where: Millennium Knickerbocker Hotel, Chicago, IL

To Learn More, Visit: www.americanconference.com/fdabootcamp-devices

For a complete list of upcoming Pharma events: Click Here

For a list of past Pharma related conference proceedings: Click Here

 

Weekly Industry News – Pharma & Healthcare

October 21st, 2013
in Healthcare, Pharmaceuticals / Biotech / Life Sciences |

 

Pharma & Healthcare – the latest on DEA probe, False Claims Act, Pfizer and more.

Costco says cooperating with DEA probe on controlled substances by Jessica Wohl  Editing by Leslie Adler and Bob Burgdorfer Posted on Reuters

Costco Wholesale Corp (COST.O) said on Wednesday that it will cooperate with the U.S. Drug Enforcement Administration in its ongoing investigation of prescriptions for controlled substances, after receiving subpoenas and warrants from the DEA. The DEA has targeted large pharmacy chains and distributors to stem the flow of prescription drugs where abuse is suspected… [ Read More ]

Supreme Court Considering False Claims Act Appeal by Brian Mahany Posted on jdsupra.com

The Supreme Court is considering an appeal from the 4th Circuit regarding the specificity necessary when pleading false claims act cases. The issue has serious implications for whistleblowers who can only document indirect frauds against government programs… [ Read More ]

 

Early Promise in Drug Trial for Fighting Cholesterol by Andrew Pollack Posted on the NYTimes.com

A new type of lipid-lowering drug being developed by Sanofi and Regeneron Pharmaceuticals cut cholesterol levels by about half in its first late-stage clinical trial, the companies will announce on Wednesday. The drug, called alirocumab, is one of a new class of potentially powerful cholesterol fighters that have excited doctors and investors alike, spurring a heated race to market among Sanofi, Amgen, Pfizer and other companies… [ Read More ]

 

Pfizer gets European approval for label update of pneumococcal conjugate vaccine Prevenar 13 by pharmaceutical-technology Posted on pharmaceutical-technology

Pfizer has received European Commission approval for updates to the summary of product characteristics (SmPC) for its pneumococcal conjugate vaccine (PCV) Prevenar 13, regarding its use in certain high-risk populations. The updated label now contains information about the use of Prevenar 13 in preterm infants, children and adolescents with sickle cell disease who were earlier treated with the 23-valent pneumococcal polysaccharide vaccine…[ Read More]

 

                                                         Related Events

 

Rx Drug PricingFDA Boot Camp - Devices EditionManaged Care Disputes and Litigation

False Claims - Legal Conference Controlled Substances cGMP - Legal Conferences

 

For a complete list of all Pharma related events: Click Here

For a complete list of all Healthcare related events: Click Here

For a complete list of all Pharma conference proceedings: Click Here 

For a complete list of all Healthcare conference proceedings: Click Here 

Weekly Industry News – Pharma & Healthcare

October 14th, 2013
in Healthcare, Legal Conferences, Pharmaceuticals / Biotech / Life Sciences |

Pharma & Healthcare – the latest on FDA approval, Sanofi, Biotech drugs, and more.

Maine Goes Rogue on Importing Prescription Drugs by Megan McArdle  Posted on Bloomberg.com

Maine has decided to allow importing of prescription drugs from countries that control the prices of said drugs. The result will be a discount for Maine residents, some decrease in the incentives and money for drug discovery and, eventually, some sort of government or private action that shuts down this gambit. Maine is not the first U.S. state government that has decided it would be nice to run its own trade policy… [ Read More ]

Gov. Brown of California Vetoes Biotech Drug Bill by  ANDREW POLLACK Posted on NYTimes.com

The first year of skirmishes in state legislatures over bills that would govern the use of cheaper versions of expensive biotechnology drugs is nearly over. Health insurers and generic drug companies have prevailed in most states over brand-name pharmaceutical companies. Their latest victory came in dramatic fashion on Saturday, when Gov. Jerry Brown of California vetoed a bill that had passed both houses of the legislature with overwhelming bipartisan support, but that critics said would limit the use of less expensive drugs… [ Read More ]

Sanofi’s Nasacort Allergy 24HR nasal spray receives FDA approval for over-the-counter use by news-medical.net on news-medical.net

Sanofi  announced today that the U.S. Food and Drug Administration (FDA) approved Nasacort® Allergy 24HR nasal spray as an over-the-counter (OTC) treatment for seasonal and year-round nasal allergies in adults and children 2 years of age and older. Nasacort is the first and only medicine in its class to be available without a prescription and will be marketed by Sanofi’s consumer healthcare division, Chattem, Inc. “We believe there is significant value in making certain types of medicines, like Nasacort, directly available to consumers,” said Anne Whitaker, President, North America Pharmaceuticals, Sanofi US.  “Allergy sufferers will benefit from having an additional treatment option and it’s a strong addition to our existing consumer health portfolio.” [Read More ]

Related Events 

FDA Boot Camp - Devices EditionControlled SubstancesRx Drug Pricing

Over the Counter Drugs  Managed Care Disputes and Litigation  False Claims and Qui Tam Enforcement

 

 

For a complete list of all Pharma upcoming events: Click Here 

 

Weekly Industry News – Pharma

October 7th, 2013
in Legal Conferences, Pharmaceuticals / Biotech / Life Sciences |

To read the complete article click on the title.

Medical-device tax repeal is an idea full of holes Posted on WP Opinions by Editorial Board

F THE Capitol Hill impasse ever ends, it will probably be through a compromise under which House Republicans abandon their demands to delay or defundObamacare — in return for a concession Senate Democrats can tolerate. One scenario involves Republican support for a spending bill in return for repealing one source of funding for the health-care law: a 2.3 percent excise tax on medical devices…. [ Read More ]

 Pharmaceutical firms paid to attend meetings of panel that advises FDA Posted on The Washington Post by Peter Whoriskey 

A scientific panel that shaped the federal government’s policy for testing the safety and effectiveness of painkillers was funded by major pharmaceutical companies that paid hundreds of thousands of dollars for the chance to affect the thinking of the Food and Drug Administration, according to hundreds of e-mails obtained by a public records request. The e-mails show that the companies paid as much as $25,000 to attend any given meeting of the panel, which had been set up by two academics to provide advice to the FDA on how to weigh the evidence from clinical trials. A leading FDA official later called the group “an essential collaborative effort.” [ Read More ]

Bliss Pharmaceutical company denies FDA allegations Posted on VibeGhana by VibeGhana

Bliss GVS Pharma limited (BLISS), at the weekend dismissed the classification of Food and Drugs Authority (FDA) that products of the company, which are distributed locally by Tobinco Pharmaceuticals Limited are fake. “We will like to state emphatically that all our products have been subjected to stringent quality standards and meet the required accreditations in India. It is unfortunate that the FDA released a statement classifying our products as fake,” a statement issued by the company said… [ Read More ]

Missouri offers tax breaks for pharmaceutical company Posted on BizJournal by Matthew Hibbard

Pharma Medica Research Inc. announced Thursday that it plans to create 320 jobs and invest $30.8 million in the St. Charles region. If the company follows through, the state will dole out more than $4.2 million in tax breaks through the Missouri Quality Jobs program, according to Amy Susan, communications director for the Missouri Department of Economic Development…. [ Read More ]

Related Events

 

Managed Care Conference   Over the Counter Drugs Legal Conference  FDA Boot Camp - Devices Edition - Legal ConferenceControlled Substances - Legal ConferenceRX Drug Pricing Boot Camp - Legal Conference    Medical Device Agreements Legal Conference ACI's Drug and Medical Device Litigation Conference

For a complete list of all pharmaceutical upcoming events: Click Here

The Government Shutdown’s Impact on FDA Matters

October 2nd, 2013
in Pharmaceuticals / Biotech / Life Sciences |

Expert Guest Blog Entry by Seth A. MailhotLeah H. Ziemba and Cameron F. Field. Article originally posted on MichaelBest.com

Today, October 1, 2013 marks the beginning of a government’s shutdown for an indefinite period of time. The Food & Drug Administration (FDA) will furlough forty-five percent of its employees on Tuesday, October 2, 2013 as it enacts its contingency plan for the government shutdown. In a document released last week, the Department of Health and Human Services (HHS) broadly outlined its methodology determining which FDA employees and services will be retained or furloughed during the shutdown.

What we know:

  • The FDA will retain employees who perform duties that are not affected by the lapse in funding, all presidential appointees, and those positions that are “related to the safety of human life.” Although the agency has not disclosed specific details, HHS has stated that the FDA will continue “limited” programs that are funded by industry fees.
  • The agency will retain 587 staff to inspect products and review imports, and an additional staff of 120 to handle emergencies and high-risk recalls. These programs will continue in some capacity because they are “related to the safety of human life.”
  • The majority of the FDA’s food safety, nutrition, and cosmetics activities will be suspended.
  • The drug review process is likely to slow as the majority of laboratory research will be halted.
  • There will also be far fewer routine establishment inspections, enforcement activities, and notification programs.

While the exact impacts of the government shutdown on FDA programs remains unclear, the food and drug industry should expect significant delays and confusion as the agency implements its shutdown contingency plan.

 
Reprinted with permission from Michael Best & Friedrich LLP. © 2013 Michael Best & Friedrich LLP

 

Next Page »

Related Events

Pharmaceuticals / Biotech / Life Sciences Events

Follow Us Here:

Pharmaceuticals / Biotech / Life Sciences Twitter